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Summary We assessed the inhibitory action of TNP-470 on lymph node metastasis in a metastatic model system using athymic nude mice.
Mice were injected subcutaneously with 5 x 106 HT-1080 cells in the right groin. TNP-470 (10, 30 and 100 mg kg-1) was injected
subcutaneously nine times in total every other day from the 7th day after tumour inoculation. Axillar and inguinal lymph nodes were dissected,
and DNA was extracted 5 weeks after tumour inoculation. Specific detection of a human P-globin-related sequence in metastasized human
tumour cells in nude mice was done by the polymerase chain reaction (PCR) technique and analysed by Southern blotting. Anti-tumour
effects on primary sites were seen only in the 100 mg kg-1 treatment group. Lymph node metastasis of transplanted HT-1080 cells was seen
in all mice of the no treatment group (5/5). On the other hand, incidences of lymph node metastasis in treated mice were 2/4 mice (100 mg
kg-1, 2/5 mice (30mg kg-1) and 4/5 mice (10 mg kg-1). The inhibition ratios of lymph node metastasis were 82.3% at 10 mg kg-1, 97.2% at 30
mg kg-1 and 97.5% at 100 mg kg-1 respectively. This agent may be useful to inhibit lymph node metastasis.
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Metastasis is a complex series of several major steps, such as
angiogenesis and growth in the primary site, invasion, intravasa-
tion, transport, arrest, attachment and extravasation as well as
angiogenesis and growth in the metastatic site. Within this series
of the metastatic cascade, angiogenesis is one of the critical steps
and anti-angiogenic therapy of malignant solid tumours has been
expected to become a new anti-cancer therapy. TNP-470, a semi-
synthetic analogue of fumagillin isolated from Aspergillus fumi-
gatus, is an anti-angiogenic agent. Recent studies have shown its
anti-tumour or anti-metastatic activity in vivo and in vitro (Ingber
et al, 1990; Kusaka et al, 1991; Yamanoto et al, 1994; Tanaka et al,
1995). Interestingly, some reports have also indicated a correlation
between angiogenesis and lymph node metastasis (Bosari et al,
1992; Guidi et al, 1994). Although we do not as yet understand
the nature of its influence on the lymphatic vessels, there is a
possibility that anti-angiogenic agents with inhibitory effects
on vascular endothelial cell growth also have the same effect on
the growth of lymphatic endothelial cells. So far, nobody has
assessed the inhibitory effect on lymph node metastasis using anti-
angiogenic agents. In this report, we assessed the inhibitory action
of TNP-470 on lymph node metastasis in a metastatic model
system using athymic nude mice. As an assay that is both highly
sensitive and quantitative, specific detection of the human 3-
globin-related sequence in metastasized human tumour cells in
nude mice was carried out using the PCR technique and analysed
by Southern blotting.
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MATERIALS AND METHODS
Mice and tumour cells
Five-week-old female athymic Balb/c nude mice were obtained
from Charles River, Japan, and maintained in a laminar air flow
cabinet under specific pathogen-free conditions. The mice used in
this study were maintained and sacrificed in accordance with the
guidelines of the committee on animal experimentation of
Kanazawa University, Takara-machi campus. As tumour cells, we
used the widely used human fibrosarcoma HT-1080 cells, originally
derived from a primary human acetabular bone malignant tumour.
The cells were maintained in Dulbecco's modified Eagle medium
supplemented with 10% fetal calf serum, and cell cultures were
maintained at 37°C in a humidified 5% carbon dioxide atmosphere.
In vivo studies
Mice were injected subcutaneously with 5 x 106 HT-1080 tumour
cells in the right groin. Mice bearing resultant tumours of 3-5 mm
on the 7th day were randomly separated into four groups as
follows: (1) no treatment, five mice; (2) treatment with TNP-470
(10 mg kg-'), five mice; (3) treatment with TNP-470 (30 mg kg-'),
five mice; and (4) treatement with TNP-470 (100 mg kg-'), ten
mice. TNP-470 was obtained from Takeda Chemical Industries
(Osaka, Japan). The agent was suspended in saline containing
ethanol (1%, 10 mg kg-'; 3%, 30 mg kg-'; and 10%, 100 mg kg-'),
5% gum arabic was injected subcutaneously every other day, and
we continued the injection nine times in total from the 7th day
after the tumour inoculation. The size of inoculated tumour was
measured in centimetres once a week using callipers, and the
tumour volume was calculated using the following formula:
tumour volume (cm3) = length x width2 / 2.
Bilateral axillar and ipsilateral inguinal lymph nodes to the inoc-
ulation site were dissected 5 weeks after the tumour inoculation.
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Intron 1 B
The 1-globin-encoding regions
Primer (A) Hu 1-1: 5'-AGAGCCATCTATTGCTTACA-3'
Primer (B) Hu P-8: 5'-TATGACATGAACTTAACCAT-3'
Probe (C) Hu ,B-2: 5'-ACACAACTGTGTTCACTAGC-3'
Figure 1 Primers (Hu 3-1 and Hu 13-8) and probe (Hu 3-2) for PCR
amplification and their locations in the human 1-globin gene. Hu 13-1 and Hu
P-8 are complementary to the (-) strand and (+) strand respectively. Hu 1-2 is
used as the probe to detect the amplified DNA fragment, and the amplified
segment is 576 bp. The filled boxes indicate the 1-globin encoding regions
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Figure 2 Correlation between primary tumour volume and weeks after
tumour inoculation on mice with or without TNP-470 treatment. *, Control;
0, TNP-470 (10 mg kg-'); O, TNP-470 (30 mg kg-'); and 0, TNP-470
(100 mg kg-1)
Figure 3 Effects of TNP-470 (10, 30 and 100 mg kg-') on lymph node
metastasis of HT-1 080 cells. TNP-470 was subcutaneously injected every
other day from 1 week after tumour inoculation into mice. Mouse lymph
nodes were then dissected at 5 weeks after tumour inoculation. Following
extraction of DNA from dissected lymph nodes, specific detection of the
human 1-globin gene in metastasized human tumour cells in nude mice
(576 bp) was done using the PCR technique and analysed by Southern
blotting
We have obtained histological sections of lymph node metastases
using mice in the no treatment group. DNA was extracted from
lymph nodes using a rapid DNA preparation method. For specific
detection of a human 1-globin-related sequence in metastasized
human tumour cells, we selected 576 bp for PCR amplification
(Figure 1). Namely, we used Hu 1-1 and Hu 1-8 as the primers and
Hu 1-2 as the probe referring to the human 1-globin-related gene
structure (Lawn et al, 1980). The DNA (1 kg) from the dissected
lymph nodes was amplified by 25 cycles of PCR (each consisting
of 2 min of denaturing at 94°C, 2 min of annealing at 550C and
2 min of extension at 720C); then the reaction products were
analysed by Southern blotting. For Southern blot analysis, the
PCR products were electrophoresed through 1.0% agarose gel
and transferred to a nylon membrane filter. After this was
hybridized to a 32P-endlabelled probe specific for the target frag-
ment, all blots were used to expose Kodak XAR film with an
intensifying screen at -80°C. Measurement of radioactivity was
done using the Fujix BA100 Bio-image-Analyzer (Fuji Photo
Film, Hamamatsu, Japan).
RESULTS
Changes in the mean volume of subcutaneal primary tumours are
shown in Figure 2. Four weeks after tumour inoculation, the treat-
ment by TNP-470 at the dose of 100 mg kg-' (total 900 mg kg-')
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Figure 4 Histological section of lymph node metastasis 5 weeks after
subcutaneal inoculation of HT-1 080 cells (H + E, x 40)
had reduced the size of the primary lesion. But the treatments at
the dose of 10 mg kg-' (total 90 mg kg-') or 30 mg kg-' (total 270
mg kg-') had no anti-tumour effect on the primary site. Lymph
node metastasis of inoculated HT-1080 cells was seen in all mice
in the no treatment group (5/5). On the other hand, incidences of
lymph node metastasis in mice treated by TNP-470 were 2/4 mice
(100 mg kg-'), 2/5 mice (30 mg kg-') and 4/5 mice (10 mg kg-').
The inhibition ratios of lymph node metastasis by TNP-470 were
82.3% at 10 mg kg-', 97.2% at 30 mg kg-' and 97.5% at 100 mg
kg-' (Figure 3). Lymph node metastasis of HT-1080 cells was
ascertained by histological examination (Figure 4). While the mice
in the no treatment group gained weight, those in treatment groups
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Figure 5 Correlation between mean weights of mice and weeks after tumour
inoculation with or without TNP-470 treatment. *, Control; , TNP-470 (10
mg kg-'); FZ, TNP-470 (30 mg kg-'); and 0, TNP-470 (100 mg kg-')
lost weight after treatment. The weight in the group whose treat-
ment was at the dose of 100 mg kg-' decreased most (Figure 5).
Six out of ten mice in this group died within 4 weeks after treat-
ment (five died at 3 weeks and one died at 4 weeks after treat-
ment). To ascertain the side-effects of TNP-470, we examined
the liver, kidney and brain ofthe mice histopathologically. Micro-
scopic appearance showed partial necrotic areas in some liver
samples with the treatment ofTNP-470 at the high dose of 100 mg
kg-' (Figure 6). The kidney and brain samples showed no signifi-
cant changes.
DISCUSSION
To develop an assay that is highly sensitive and quantitative,
specific detection of a segment of the human 3-globin gene in
metastasized human tumour cells in nude mice was done using a
PCR technique and analysed by Southern blotting. This sensitive
method for the specific detection of metastasized human tumour
cells was first used in the metastatic model system using embry-
onic chicks by Endo et al (1990). In this study, we applied this
method in nude mice for the assessment oflymph node metastasis.
From the basic data on this metastatic model system using nude
mice, we know that spontaneous lymph node metastasis could be
detected from 5 weeks after subcutaneous inoculation of 5 x 106
HT-1080 cells. Concerning the sensitivity of this assay, we know
that a concentration of 1 x 105 ,ug of HT-1080 DNA could be
detected under these experimental conditions as the result of
Southern blot analysis of PCR amplification products from serial
dilutions of HT-1080 genomic DNA in normal mouse DNA. We
also ascertained that DNA from a normal mouse did not produce
any PCR-amplified fragments (data not shown). Using this model
system, we could quantitatively assess the lymph node metastasis.
Anti-angiogenic therapy is anticipated as apromising strategy to
inhibit angiogenesis-dependent tumour growth and metastasis. In
experiments in vivo or in vitro, anti-tumour or anti-metastatic
effects ofTNP-470 have been reported, as mentioned earlier. As to
Figure 6 Microscopic appearance of mice liver treated with TNP-470 at the
dose of 100 mg kg-' (900 mg kg-' in total). Partial necrotic change was
5 detected in some livers (H + E, x 200)
the inhibitory action ofTNP-470 on endothelial cells, it was found
that this agent inhibited the growth of HUVE cells in a biphasic
manner - cytostatic and cytotoxic (Kusaka et al, 1994). Exposure
to TNP-470 has caused arrest in theGO/GI phases of HUVE cells,
and this cytostatic inhibition has been suspected to be important in
the anti-angiogenic activity (Hori et al, 1994; Kusaka et al, 1994);
but the exact detailed mechanism has been obscure. Concerning
inhibitory action of TNP-470 on angiogenesis, there was a report
that both vascular endothelial growth factor (VEGF)- and basic
fibroblast growth factor (bFGF)-induced cell growth were inhib-
ited by this anti-angiogenic agent (Toi et al, 1994). Among angio-
genic factors, VEGF is known to be an endothelial cell-specific
mitogen involved in tumour neovascularization, and bFGF is also
known as an important autocrine - intracrine regulator ofendothe-
lial cells. As the result of the reverse transcription - polymerase
chain reaction (RT-PCR) method, we ascertained that HT-1080
tumour cells inoculated in mice greatly expressed VEGF mRNA
and bFGF. To assess the angiogenesis in the lymph nodes, we also
examined human VEGF and bFGF mRNA expression; however,
the metastatic tissues in lymph nodes were too small to assess
them. We could not ascertain any depressed expression of these
angiogenic factors at the metastatic site in treated mice.
On clinical examination, some reports have indicated a signifi-
cant correlation between the incidence of metastases and tumour
angiogenesis, and tumour angiogenesis is associated with a worse
prognosis in some solid neoplasms (Chodak et al, 1980; Weidner
et al, 1991). Interestingly, some reports have also indicated a corre-
lation between lymph node metastasis and angiogenesis (Bosari
et al, 1992; Guidi et al, 1994). Although the action of angiogenic
factors on the lymphatic vessels is not clear, there is a possibility
that anti-angiogenic agents with inhibitory effects on vascular
endothelial cell growth also have the same effect on the growth of
lymphatic endothelial cells. The results of our study seem to
support this hypothesis. In this study, lymph node metastasis was
effectively inhibited at any dose level of TNP-470. Even at a low
dose (10 mg kg-') of TNP-470, the inhibition of lymph node
metastasis could be recognized. On the other hand, except for the
group with treatment at the high dose of 100 mg kg-', the anti-
tumour effect of TNP-470 on the primary site was not significant,
i.e. the primary tumour size in the treatment group with TNP-470
at the dose of 10 or 30 mg kg-' was almost the same as that of the
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no treatment group. This agent seems to be more effective for the
inhibition of lymph node metastasis than inhibition of growth in
the primary site. In other words, the anti-angiogenic action ofthis
agent on the pre-existing endothelium ofmicrovessels may be less
effective than that on newly formed or coming neovascula. As one
of strategies for the inhibition of lymph node metastasis, this anti-
angiogenic agent may be useful forpatients with curative resection
ofangiogenesis-dependent primary neoplasms.
As to side-effects ofthis agent, severe adverse effects have never
been reported. Weconfirm necrotic liverchanges in the perivenular
area in some mice with a high dose ofTNP-470 (100 mg kg-'). As
described earlier, six out of ten mice in this group died after treat-
ment. As to the cause ofdeath, we cannot deny the possibility that
they were terminated when moribund. Clearly, drug-induced side-
effects must be carefully investigated when this agent is used for a
long period, even ifthe dose at any one time is not high.
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